BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen M, Nie J, Liu Y, Li X, Zhang Y, Brock MV, Feng K, Wu Z, Li X, Shi L, Li S, Guo M, Mei Q, Han W. Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer. Int J Cancer 2018;143:1530-40. [PMID: 29663379 DOI: 10.1002/ijc.31531] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Juat DJ, Hachey SJ, Billimek J, Del Rosario MP, Nelson EL, Hughes CCW, Zell JA. Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review. The Oncologist 2022. [DOI: 10.1093/oncolo/oyab038] [Reference Citation Analysis]
2 Hu C, Liu X, Zeng Y, Liu J, Wu F. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics 2021;13:166. [PMID: 34452630 DOI: 10.1186/s13148-021-01154-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Steinbügl M, Nemes K, Johann P, Kröncke T, Tüchert S, da Costa MJG, Ebinger M, Schüller U, Sehested A, Hauser P, Reinhard H, Sumerauer D, Hettmer S, Jakob M, Hasselblatt M, Siebert R, Witt O, Gerss J, Kerl K, Frühwald MC. Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. Pediatr Blood Cancer 2021;:e29267. [PMID: 34347371 DOI: 10.1002/pbc.29267] [Reference Citation Analysis]
4 Yan X, Zhao Y, Liu Y, Yang Q, Dong L, Wu Z, Nie J, Chen D, Bai M, Ti D, Feng K, Han W. Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer. Front Oncol 2020;10:558572. [PMID: 33194624 DOI: 10.3389/fonc.2020.558572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wu M, Sheng L, Cheng M, Zhang H, Jiang Y, Lin S, Liang Y, Zhu F, Liu Z, Zhang Y, Zhang X, Gao Q, Chen D, Li J, Li Y. Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells. Oncogene 2019;38:5425-39. [PMID: 30918330 DOI: 10.1038/s41388-019-0799-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
6 Feng YL, Chen DQ, Vaziri ND, Guo Y, Zhao YY. Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis. Med Res Rev 2020;40:54-78. [PMID: 31131921 DOI: 10.1002/med.21596] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
7 Takeshima H, Yoda Y, Wakabayashi M, Hattori N, Yamashita S, Ushijima T. Low-dose DNA demethylating therapy induces reprogramming of diverse cancer-related pathways at the single-cell level. Clin Epigenetics 2020;12:142. [PMID: 32958049 DOI: 10.1186/s13148-020-00937-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Wong KK. DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications. Cell Oncol (Dordr) 2020;43:779-92. [PMID: 32504382 DOI: 10.1007/s13402-020-00526-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
9 Kobelt D, Dahlmann M, Dumbani M, Güllü N, Kortüm B, Vílchez MEA, Stein U, Walther W. Small Ones to Fight a Big Problem-Intervention of Cancer Metastasis by Small Molecules. Cancers (Basel) 2020;12:E1454. [PMID: 32503267 DOI: 10.3390/cancers12061454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Bai RL, Wang NY, Zhao LL, Zhang YF, Cui JW. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00169-7. [PMID: 34538570 DOI: 10.1016/j.hbpd.2021.08.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhang H, Dong W, Zhao H, Zeng Z, Zhang F, Hu Y, Li Q, Chen J, Meng E, Xiao W. Homozygous deletion of the HLA-B gene as an acquired-resistance mechanism to nivolumab in a patient with lung adenocarcinoma: a case report. Ann Transl Med 2021;9:1506. [PMID: 34805368 DOI: 10.21037/atm-21-3825] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]